Benzinga - by Benzinga Insights, Benzinga Staff Writer.
KEVIN GORDON, Director at Progyny (NASDAQ:PGNY), reported an insider sell on December 14, according to a new SEC filing.
What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, GORDON sold 2,500 shares of Progyny. The total transaction value is $89,825.
As of Thursday morning, Progyny shares are up by 1.11%, currently priced at $36.52.
Delving into Progyny's Background Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Progyny: A Financial Overview Revenue Growth: Over the 3 months period, Progyny showcased positive performance, achieving a revenue growth rate of 36.77% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
- Gross Margin: The company issues a cost efficiency warning with a low gross margin of 22.29%, indicating potential difficulties in maintaining profitability compared to its peers.
- Earnings per Share (EPS): Progyny's EPS is below the industry average. The company faced challenges with a current EPS of 0.17. This suggests a potential decline in earnings.
Valuation Metrics:
- Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 70.88 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
- Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.52 as compared to the industry average, the stock might be considered overvalued based on sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Progyny's EV/EBITDA ratio stands at 58.51, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Exploring the Significance of Insider Trading In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
Breaking Down the Significance of Transaction Codes When dissecting transactions, the focal point for investors is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Progyny's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.